Novo Nordisk

Odense, Denmark

healthcarediabetesobesityrare diseaseschronic diseasessustainabilitywomen in sciencelong-term healthmedical researchcommunity engagementinnovation

About

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, with production facilities in nine countries and affiliates or offices in five. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes care medications and devices. Novo Nordisk makes the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy. Novo Nordisk is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. Read more